Vaccine (Recombinant protein vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by NOVAVAX
NVX-CoV2601 is a protein subunit vaccine containing recombinant SARS-CoV-2 spike protein antigen formulated with Matrix-M adjuvant. It is administered as a single intramuscular injection and is studied for COVID-19 prevention.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05925127 | Phase 2/3 | COVID-19 | Completed | NVAX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID-19
Updated Oct 3, 2026. Something wrong or missing? Report it on the NVAX page.
See NVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVAX catalysts and pipeline →